Key result
Percutaneous left atrial appendage occlusion demonstrates high procedural success and acceptable safety in observational registries, though multicenter randomized trials in anticoagulation-intolerant patients remain needed.
Why the study?
Does percutaneous left atrial appendage occlusion safely and effectively prevent thromboembolic events in patients with nonvalvular atrial fibrillation who cannot tolerate long-term oral anticoagulation?
Does percutaneous left atrial appendage occlusion safely and effectively prevent thromboembolic events in patients with nonvalvular atrial fibrillation who cannot tolerate long-term oral anticoagulation?
Answers are grounded in this paper and cite their sources.
This editorial highlights that while clinical experience and registry data support the feasibility and safety of percutaneous LAA occlusion in OAC-intolerant AF patients, definitive multicenter randomized controlled trials are still required to establish its role alongside modern DOACs.
The first prosthesis developed for this purpose, called PLAATO, was tested early in the last decade by Horst Sievert et al.4 and consisted of a nitinol structure, covered by an expanded polytetrafluoroethylene (ePTFE) occlusive membrane. The clinical study published in 2002 showed that the concept of percutaneous LAA occlusion was feasible; however, the prosthesis use was discontinued in 2005, due to the considerable number of complications such as cardiac tamponade, residual leaks, prosthesis protrusion towards the atrial cavity and, in some cases, lack of neo-endothelization of the prosthesis with formation of local thrombi.5 On the other hand, the experience obtained with the implantation of this prosthesis was important for the development of more effective devices.
No takes yet. Share an insight, caveat, or question.
Pisani et al. (2019) conducted an editorial in Nonvalvular atrial fibrillation at high risk of thromboembolism with contraindications or intolerance to oral anticoagulants. Percutaneous left atrial appendage occlusion (Watchman, Amplatzer Cardiac Plug, Amplatzer Amulet) vs. Oral anticoagulation (warfarin or direct-acting oral anticoagulants) was evaluated on Stroke, systemic embolization, and procedural safety complications. Percutaneous left atrial appendage occlusion demonstrates high procedural success and acceptable safety in observational registries, though multicenter randomized trials in anticoagulation-intolerant patients remain needed.
Synapse has enriched 10 related papers. Consider them for comparative context: